vs
牛津地产（IIPR）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
牛津地产的季度营收约是MESA LABORATORIES INC的1.0倍（$66.7M vs $65.1M），牛津地产净利率更高（47.8% vs 5.6%，领先42.2%），MESA LABORATORIES INC同比增速更快（3.6% vs -13.1%），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -6.0%）
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
IIPR vs MLAB — 直观对比
营收规模更大
IIPR
是对方的1.0倍
$65.1M
营收增速更快
MLAB
高出16.8%
-13.1%
净利率更高
IIPR
高出42.2%
5.6%
两年增速更快
MLAB
近两年复合增速
-6.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $66.7M | $65.1M |
| 净利润 | $31.8M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 47.8% | 12.2% |
| 净利率 | 47.8% | 5.6% |
| 营收同比 | -13.1% | 3.6% |
| 净利润同比 | -20.4% | 316.6% |
| 每股收益（稀释后） | $1.07 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IIPRMLAB
| Q4 25 | $66.7M | $65.1M | ||
| Q3 25 | $64.7M | $60.7M | ||
| Q2 25 | $62.9M | $59.5M | ||
| Q1 25 | $71.7M | $62.1M | ||
| Q4 24 | $76.7M | $62.8M | ||
| Q3 24 | $76.5M | $57.8M | ||
| Q2 24 | $79.8M | $58.2M | ||
| Q1 24 | $75.5M | $58.9M |
净利润IIPRMLAB
| Q4 25 | $31.8M | $3.6M | ||
| Q3 25 | $29.3M | $2.5M | ||
| Q2 25 | $26.0M | $4.7M | ||
| Q1 25 | $31.1M | $-7.1M | ||
| Q4 24 | $40.0M | $-1.7M | ||
| Q3 24 | $40.2M | $3.4M | ||
| Q2 24 | $42.0M | $3.4M | ||
| Q1 24 | $39.4M | $-254.6M |
毛利率IIPRMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率IIPRMLAB
| Q4 25 | 47.8% | 12.2% | ||
| Q3 25 | 45.5% | 7.8% | ||
| Q2 25 | 45.9% | 5.1% | ||
| Q1 25 | 47.4% | 2.4% | ||
| Q4 24 | 54.7% | 9.2% | ||
| Q3 24 | 54.8% | 6.1% | ||
| Q2 24 | 53.1% | 9.6% | ||
| Q1 24 | 55.7% | -460.6% |
净利率IIPRMLAB
| Q4 25 | 47.8% | 5.6% | ||
| Q3 25 | 45.3% | 4.1% | ||
| Q2 25 | 41.4% | 8.0% | ||
| Q1 25 | 43.3% | -11.4% | ||
| Q4 24 | 52.2% | -2.7% | ||
| Q3 24 | 52.6% | 5.9% | ||
| Q2 24 | 52.6% | 5.8% | ||
| Q1 24 | 52.3% | -432.2% |
每股收益（稀释后）IIPRMLAB
| Q4 25 | $1.07 | $0.65 | ||
| Q3 25 | $0.97 | $0.45 | ||
| Q2 25 | $0.86 | $0.85 | ||
| Q1 25 | $1.03 | $-1.30 | ||
| Q4 24 | $1.35 | $-0.31 | ||
| Q3 24 | $1.37 | $0.63 | ||
| Q2 24 | $1.44 | $0.62 | ||
| Q1 24 | $1.36 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $47.6M | $29.0M |
| 总债务越低越好 | $393.7M | $68.4M |
| 股东权益账面价值 | $1.8B | $186.7M |
| 总资产 | $2.4B | $434.8M |
| 负债/权益比越低杠杆越低 | 0.21× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资IIPRMLAB
| Q4 25 | $47.6M | $29.0M | ||
| Q3 25 | $41.9M | $20.4M | ||
| Q2 25 | $104.9M | $21.3M | ||
| Q1 25 | $133.3M | $27.3M | ||
| Q4 24 | $151.2M | $27.3M | ||
| Q3 24 | $172.4M | $24.3M | ||
| Q2 24 | $160.9M | $28.5M | ||
| Q1 24 | $173.5M | $28.2M |
总债务IIPRMLAB
| Q4 25 | $393.7M | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益IIPRMLAB
| Q4 25 | $1.8B | $186.7M | ||
| Q3 25 | $1.9B | $178.5M | ||
| Q2 25 | $1.9B | $172.5M | ||
| Q1 25 | $1.9B | $159.8M | ||
| Q4 24 | $1.9B | $155.2M | ||
| Q3 24 | $1.9B | $161.5M | ||
| Q2 24 | $1.9B | $150.7M | ||
| Q1 24 | $2.0B | $145.4M |
总资产IIPRMLAB
| Q4 25 | $2.4B | $434.8M | ||
| Q3 25 | $2.3B | $430.4M | ||
| Q2 25 | $2.3B | $435.7M | ||
| Q1 25 | $2.4B | $433.3M | ||
| Q4 24 | $2.4B | $433.3M | ||
| Q3 24 | $2.4B | $454.1M | ||
| Q2 24 | $2.4B | $440.4M | ||
| Q1 24 | $2.4B | $446.8M |
负债/权益比IIPRMLAB
| Q4 25 | 0.21× | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $198.2M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | 6.22× | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流IIPRMLAB
| Q4 25 | $198.2M | $18.8M | ||
| Q3 25 | $45.6M | $8.2M | ||
| Q2 25 | $48.4M | $1.9M | ||
| Q1 25 | $54.2M | $12.7M | ||
| Q4 24 | $258.4M | $18.1M | ||
| Q3 24 | $64.9M | $5.3M | ||
| Q2 24 | $64.2M | $10.7M | ||
| Q1 24 | $71.6M | $12.9M |
自由现金流IIPRMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率IIPRMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度IIPRMLAB
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.9% |
现金转化率IIPRMLAB
| Q4 25 | 6.22× | 5.17× | ||
| Q3 25 | 1.56× | 3.32× | ||
| Q2 25 | 1.86× | 0.40× | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 6.46× | — | ||
| Q3 24 | 1.61× | 1.54× | ||
| Q2 24 | 1.53× | 3.17× | ||
| Q1 24 | 1.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IIPR
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
